Get started
Author

Andrzej Smyk

Observed names: A Smyk, Smyk, Andrzej
ORCID: 0000-0002-7794-112X
Observed ORCID: 0000-0002-7794-112X
OpenAlex ID: A5046906609
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
2023 · Bruno Brochet, Alessandra Solari, et al. · Multiple Sclerosis Journal · 24
PDF
162. Long-term Effectiveness of Cladribine Tablets over 4 years in Relapsing Multiple Sclerosis: Results from the MAGNIFY-MS Extension Study
2024 · Nicola De Stefano, Patrick Vermersch, et al. · Multiple Sclerosis and Related Disorders · 8
161. Long-term Effects of Cladribine Tablets Treatment on Cognition, Relapses, MRI, and Safety Outcomes in Patients with Relapsing Multiple Sclerosis: 4‑year Results from the CLARIFY-MS Extension study
2024 · Krzysztof Selmaj, Dawn Langdon, et al. · Multiple Sclerosis and Related Disorders · 4
Early onset of Action and Sustained Efficacy of MRI Outcomes during Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-Year MAGNIFY-MS Study
2023 · Nicola De Stefano, Anat Achiron, et al. · Multiple Sclerosis and Related Disorders · 4
Improvements in Quality of Life Over 2 Years in Patients Treated with Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: Final Analysis of CLARIFY-MS
2023 · Alessandra Solari, Xavier Montalban, et al. · Multiple Sclerosis and Related Disorders · 2
Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study
2026 · Bruno Brochet, Dawn Langdon, et al. · Neurology and Therapy · 1
PDF
Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary
2024 · Bruno Brochet, Alessandra Solari, et al. · Neurodegenerative Disease Management · 1
PDF
Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study (P6-3.018)
2023 · Nicola De Stefano, Anat Achiron, et al. · Neurology · 1
Cognitive Resilience and Improvements in Health-Related Quality of Life Over 4 Years in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results from the CLARIFY-MS Extension Study
2026 · J Lechner-Scott, D Langdon, et al. · Multiple Sclerosis and Related Disorders
Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study
2026 · Bruno Brochet, Dawn Langdon, et al. · Neurology and Therapy
PDF
Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study
2026 · Bruno Brochet, Dawn Langdon, et al. · Neurology and Therapy
PDF
Efficacité à long terme de la Cladribine comprimé (CladT) sur 4 ans dans la sclérose en plaques récurrente (SEP R) : résultats de l’étude d’extension MAGNIFY-MS
2025 · Nicola De Stefano, Patrick Vermersch, et al. · Revue Neurologique
Time to Qualifying Relapse by Previous Disease-Modifying Therapy Status in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets Over 2 Years in the CLARIFY-MS Study
2023 · Francesco Patti, Bruno Brochet, et al. · Multiple Sclerosis and Related Disorders
Применение Телесно-ориентированной Психокоррекции В Комплексной Терапии Бронхиальной Астмы
2020 · Andrzej Smyk
Choroba Gauchera – zalecenia dotyczące rozpoznawania, leczenia i monitorowania
2017 · Piotr Hasiński, Mirosław Bik-Multanowski, et al. · Acta Haematologica Polonica
PDF
Новый перспективный подход к психологической коррекции алекситимии при бронхиальной астме
2015 · Andrzej Smyk, Е. В. Маркова, et al. · Мир науки, культуры, образования
Works count: 18
Citation count: 45
H-index: 4
I10-index: 1
Year
Topic
Type